



Patients with Metastatic Melanoma Treated with High-Dose IL-2 - Nonresponders



AJCC Staging 2001: Patients with Melanoma




CLINICAL RESPONSES IN PATIENTS RECEIVING ADOPTIVE CELL TRANSFER OF TIL FOLLOWING NON-MYELOABLATIVE CHEMOTHERAPY

Patient	Sites of evaluable disease	Response	Duration in months (as of 2/1/03)	Comments
AK	Axillary, mesenteric, pelvic lymph nodes	PR	27+	99% , residual resected; now NED
MD	Cutaneous, subcutaneous	PR	2	Recurrence resected; NED
DK	Cutaneous, subcutaneous	PR	8	Received i.v. and i.a. cells
SF	Subcutaneous, lung, intraperitoneal	PR	18+	
DM	Cutaneous, subcutaneous	PR	9+	
HS	Cutaneous, subcutaneous	PR	12+	99%, residual resected; NED
JK	Subcutaneous, liver, pericardial	Mixed	4+	Complete regression of multiple liver metastases; new subcutaneous

(Science, 298:850-854, 2002)

AJCC Staging 2001: Patients with Melanoma



Patients with Metastatic Melanoma Treated with High-Dose IL-2 - Nonresponders

